KPV
Lysine-Proline-Valine
Regulatory Status
Not FDA-approved. FDA has discussed KPV in safety-risk language and scheduled KPV-related bulk drug substances for July 2026 PCAC review.
FDA · Updated May 2026
Not licensed by MHRA. Available as research chemical.
MHRA · Updated Mar 2026
Not scheduled by TGA. Limited availability.
TGA · Updated Mar 2026
Not currently on WADA prohibited list.
WADA · Updated Jan 2026
What Is KPV?
KPV is a naturally occurring tripeptide consisting of three amino acids — lysine, proline, and valine. It is derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH), a neuropeptide with well-documented anti-inflammatory and immunomodulatory properties. While alpha-MSH itself is a 13-amino acid peptide, research has identified KPV as one of the smallest fragments that retains significant anti-inflammatory activity [1].
The tripeptide was first characterised for its anti-inflammatory properties in the late 1990s and early 2000s. Its small size — just three amino acids — gives it advantages in terms of stability and potential for oral and topical administration. KPV does not activate melanocortin receptors as strongly as the full alpha-MSH molecule, which means it may exert anti-inflammatory effects without significant pigmentation changes [2].
KPV is not approved by the FDA, MHRA, or TGA for human therapeutic use. Research is primarily in animal and in-vitro models. FDA has also scheduled KPV-related bulk drug substances for the July 2026 Pharmacy Compounding Advisory Committee review, so compounded-use claims should be treated as unsettled regulatory questions rather than settled access pathways.
Mechanism of Action
KPV’s anti-inflammatory activity appears to operate through several pathways:
NF-kB pathway inhibition. The most studied mechanism of KPV is its ability to inhibit the nuclear factor kappa-B (NF-kB) signalling pathway. NF-kB is a master regulator of inflammatory gene expression, controlling the production of pro-inflammatory cytokines including TNF-alpha, IL-1, IL-6, and IL-8. In-vitro studies suggest that KPV may enter cells and directly interact with NF-kB signalling components, reducing inflammatory gene transcription [3].
Inflammatory cytokine reduction. Cell culture and animal studies indicate that KPV may reduce the production of multiple pro-inflammatory cytokines. This broad anti-inflammatory effect distinguishes it from drugs that target single cytokines [4].
Antimicrobial properties. Research suggests that KPV may possess direct antimicrobial activity against certain bacterial strains, including Staphylococcus aureus and Candida albicans. The mechanism appears to involve disruption of microbial cell membranes [5].
Gut epithelial barrier support. Animal studies suggest KPV may help maintain intestinal epithelial barrier integrity under inflammatory conditions, potentially reducing bacterial translocation and immune activation [6].
Research and Evidence
Gut Inflammation and Inflammatory Bowel Disease
The most active area of KPV research is its potential role in gut inflammation. Studies in murine colitis models have demonstrated that KPV administration — including oral delivery — may reduce markers of intestinal inflammation. Research by Dalmasso et al. (2008) showed that orally administered KPV was able to reduce colonic inflammation in a dextran sodium sulfate (DSS) colitis model, with KPV appearing to be absorbed by colonic epithelial cells and exerting anti-inflammatory effects locally [3].
Subsequent studies have explored KPV-loaded nanoparticle delivery systems designed to target the inflamed colon specifically, showing enhanced anti-inflammatory effects in animal models of colitis [7]. This research suggests potential for targeted gut delivery, though no human clinical trials have been conducted.
Skin Inflammation
Given its origin from alpha-MSH — a peptide with known roles in skin biology — KPV has been investigated for dermatological applications. In-vitro studies using human keratinocytes suggest that KPV may reduce inflammatory responses in skin cells. This has led to interest in topical KPV formulations for inflammatory skin conditions, though human clinical data is not yet available [8].
Antimicrobial Activity
Research has demonstrated that KPV exhibits antimicrobial activity against several pathogens in laboratory settings. Studies suggest the peptide may disrupt microbial cell membranes, providing a mechanism distinct from conventional antibiotics. This dual anti-inflammatory and antimicrobial profile is of particular interest for conditions involving both infection and inflammation [5].
Dosage and Administration
Important: The following information reflects dosages referenced in research literature and community protocols. KPV is not an approved medication, and no official dosing guidelines exist. Always consult a qualified healthcare provider.
Community-Referenced Protocols
- Oral: 200-500 mcg per day, sometimes formulated in enteric capsules designed for colonic release
- Subcutaneous: 200-500 mcg per day
- Topical: Variable concentrations in cream or serum formulations
Oral administration is of particular interest for KPV due to research suggesting the peptide can be absorbed by colonic epithelial cells and act locally on gut inflammation.
Side Effects and Safety
KPV’s safety profile in humans has not been established through clinical trials. Available information is based on preclinical research:
- Animal studies have not reported significant toxicity at doses studied
- As a naturally occurring fragment of alpha-MSH, it is present in the human body at low concentrations
- Unlike full-length alpha-MSH, KPV has minimal melanocortin receptor activation, reducing risk of pigmentation effects
- Long-term safety is unknown
- Interactions with medications have not been characterised
Frequently Asked Questions
How is KPV different from BPC-157 for gut health?
While both peptides are studied for gut-related applications, they work through different mechanisms. BPC-157 research focuses on gut mucosal healing through angiogenesis and growth factor upregulation. KPV research focuses on reducing gut inflammation through NF-kB inhibition and inflammatory cytokine reduction. They address different aspects of gut health — repair versus inflammation control.
Can KPV be taken orally?
Research suggests that KPV can be absorbed by intestinal epithelial cells when taken orally, and animal studies have used oral administration. Some formulations use enteric coatings for targeted colonic delivery. However, oral bioavailability in humans has not been formally characterised.
Does KPV cause skin darkening?
Unlike full-length alpha-MSH or its analogue melanotan, KPV has minimal melanocortin receptor activation. Research suggests it does not significantly stimulate melanogenesis (pigment production) at the doses studied.
Is KPV banned by WADA?
KPV is not currently listed on the WADA prohibited list. However, athletes should verify current regulations, as WADA updates its prohibited list annually and the S0 category broadly covers non-approved substances.
References
References
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocrine Reviews. 2008;29(5):581-602.
- Getting SJ, et al. Molecular determinants of the anti-inflammatory actions of the melanocortin peptides. Trends in Pharmacological Sciences. 2003;24(6):276-279.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331.
- Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233-239.
- Laroui H, et al. Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon. Biomaterials. 2011;32(4):1218-1228.
- Xiao B, et al. Nanoparticles with surface antibody against CD98 and carrying KPV tripeptide for oral treatment of colitis. Biomaterials. 2014;35(25):7092-7102.
- Luger TA, et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences. 2003;994:133-140.
- FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. KPV-related bulk drug substances are listed for discussion.
Continue Reading